Developing first-in-class cardiovascular biopharmaceuticals that target natural repair pathways.


George Arida, Managing Director

George Arida, Chairman - George Arida is a Managing Director at Venture Investors with a focus on the firm's healthcare practice. George currently serves as the Board Chair for Zystor Therapeutics and Nerites and as a member of the Boards of Directors at Celleration, Chromatin and ProCertus BioPharm. He also serves on the Board of the Mid-America Healthcare Investors Network, an association of over forty regional venture capital firms active in early stage healthcare investing. George previously served as the CFO for a financial consulting and brokerage firm. Prior to this, he spent five years at U.S. Filter Corporation in management and technical marketing positions, four years with Betz Laboratories in technical sales and field service management, and two years at Alar Engineering as a Process Engineer. George has a Bachelor of Science degree in Chemical Engineering from the University of Illinois at Urbana-Champaign and a Master of Business Administration degree with high honors from the University of Chicago.

Rahul Aras, President and CEO

Rahul Aras, Ph.D. (Co-Founder, President and Chief Executive Officer) is the founding CEO for Juventas Therapeutics. Dr. Aras has led the Company since its inception in 2007 and has leveraged his scientific research and business experience to lead Juventas towards commercialization of its innovative therapies. Dr. Aras has successfully transitioned Juventas’ technologies from the laboratory into mid-stage clinical trials. Prior to leading Juventas, Dr. Aras was the Director of Life Science Commercialization at Cleveland Clinic Innovations where he managed commercialization of all biotechnology and pharmaceutical related technologies developed at Cleveland Clinic. Dr. Aras has held research positions at Vanderbilt University Medical Center and Massachusetts General Hospital and has published articles in several leading scientific journals. He received a B.S. from Tufts University and a Ph.D. in biomedical research from New York University.

James C. Boland, Vice Chairman

James C. Boland– Jim Boland spent 34 years of his career with Ernst & Young. A native of Cleveland, Jim joined Ernst & Young after serving two years as an officer in the United States Army. He became a partner in 1976 and served as a member of the Firm’s Management Committee from 1988 to 1997. He also had operating responsibility as Vice Chairman and Regional Managing Partner of Ernst & Young’s Central Region from 1988 to 1996. Jim joined the Cavaliers Operating Company in 1998 as President and Chief Executive Officer and, effective January 2003, became Vice Chairman. Jim serves or has served on the Boards of The Sherwin-Williams Company, Invacare Corporation, The Goodyear Tire and Rubber Company, International Steel Group and DDR Corporation, as well as several private companies. He also serves as Chairman of Jobs Ohio and serves on the Board of the Center for Global Business Studies in Washington D.C.

Suzette Dutch

Suzette Dutch - Suzette is a co-founder and Managing Partner of Triathlon Medical Venture Partners. She brings over 20 years of venture investing and 10 years of operating industry experience in pharmaceuticals, devices, and diagnostics. Suzette helps portfolio companies navigate the regulatory path and assists them with clinical trials, strategic marketing, business development and financial modeling. Suzette also directs the Fund’s financial and legal matters. Suzette was a Managing Director of Senmed Medical Ventures and served as a member of the Investment Committee from its creation in 1987 until 2003. She led strategic planning, market and industry research, clinical/regulatory and business analysis due diligence efforts for start-up through later stage investments. Prior to joining Senmed, Suzette served as Manager of Product Strategies for Sencorp’s surgical stapling business. She started her career at SmithKline's Pharmaceutical Division in market research supporting clinical study design and regulatory and reimbursement planning. She was responsible for integrating SmithKline's acquisitions of Allergan, Beckman, and the Clinical Laboratories. She holds a BA degree in Economics, cum laude, from Case Western Reserve University and an MBA in Finance and Decision Science from Wharton Graduate School, University of Pennsylvania.

Jack Miner

Jack Miner – Jack Miner serves as Managing Director, Cleveland Clinic Ventures. Prior to joining Cleveland Clinic, Jack was responsible for launching startups and creating business formation infrastructure around University intellectual property for the Office of Technology Transfer (OTT) at the University of Michigan. Jack joined the University of Michigan in 2011 and helped launch more than 50 startup companies while managing a portfolio of more than 300 companies. His team helped life sciences, physical sciences and digital technology companies launch successfully with over 78% of companies still in existence since 1987. Companies from the Michigan OTT portfolio have raised billions of dollars including $700 Million in venture capital between 2011 and 2016. Prior to joining the UM Tech Transfer team, Jack was part of seven venture capital-backed software companies and a member at Fortune100 information technology organizations Computer Associates and Amdahl. Jack has a BA in Economics from the University of Michigan and a Masters in Management from Northwestern University, Kellogg Graduate School of Management.

Roger Newton

Roger Newton, Ph.D. – Roger Newton, Ph.D. is Executive Chairman and Chief Scientific Officer of Esperion Therapeutics, Inc. Prior to his current role, he was Senior Vice President, Pfizer Global R&D and Director, Esperion Therapeutics, a Pfizer, Inc. company. He was co-founder, President & CEO of the original Esperion founded in July 1998. Under Roger's leadership and the team's effort, Esperion raised more than $200 million in funding, building a portfolio of biopharmaceuticals and small molecule product candidates, and was acquired by Pfizer for $1.3 billion in February 2004. Pfizer then divested Esperion in May 2008 and Roger restarted the company as an independent enterprise with $23 million in venture capital funding. Prior to founding the original Esperion, Roger was with Warner Lambert/Parke-Davis (now Pfizer) from 1981-1998. As a Distinguished Scientist and Chairman of the Atherosclerosis Drug Discovery Team, he co-discovered and was the product champion of what is now the most prescribed cholesterol-reducing drug in the world, atorvastatin (Lipitor®).

Matthew Pollman

Matthew Pollman, M.D. – Matthew Pollman, M.D. is a cardiologist and cardiovascular molecular biologist with over ten years of experience leading R&D initiatives in the biotechnology, diagnostics, and medical devices healthcare arenas. He is currently the Chairman of Guided Interventions, LLC, a startup company developing a product to help cardiologists better assess the physiological impact of coronary artery blockages. Prior to this latest venture, Dr. Pollman served as Founder, President and Chief Scientific Officer of CV Ingenuity, an early stage company developing a combination drug/device therapy for the treatment of cardiovascular disease, recently acquired by Covidien. Additionally, he has served as Medical Director, Research and Development, Abbott Vascular serving as principal medical and scientific strategist and advisor for the R&D pipeline and Business Development portfolios; guiding both internal and external technology investments. Prior to Abbott's acquisition of Guidant Corporation, Dr. Pollman directed their New Ventures group, a 30+ member in-house start-up incubator responsible for identifying, exploring and incubating significant new business opportunities. Dr. Pollman received his medical training at the University of California San Francisco, Stanford University and Brigham and Women's Hospital. He has served as a full-time faculty member at Harvard Medical School and Morehouse School of Medicine.

Linda Tufts

Linda Tufts – Linda Tufts is a Founding Partner in Fletcher Spaght Ventures, and is also Vice President and head of the Healthcare Practice Group at Fletcher Spaght, the firm's consulting business. Prior to joining Fletcher Spaght in 1989, Linda was affiliated with the Sony Corporation of America as an internal consultant, participating in a worldwide effort to streamline the process to commercialize new products and technologies. Previously, Linda was a Manager with Bain & Company in their Boston office. At Bain, Linda managed assignments in healthcare and service industries and was also affiliated with a Bain-Baxter joint program, Travenol Management Services. Before joining Bain, Linda was a Consultant with Strategic Planning Associates, now Mercer Management Consulting, in their Washington, D.C. office, where her work included strategy and financial consulting assignments in many industries. Prior to business school, Linda worked as an Electrical Engineer.